The Money Is Moving — But Don't Confuse Funding With a Fix

The Coalition for Epidemic Preparedness Innovations (CEPI) announced June 1, 2026 that it will urgently accelerate three experimental vaccines targeting the Bundibugyo virus. The candidates come from three developers: Moderna, the University of Oxford partnered with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).

The dollar breakdown, per Euronews: Moderna gets up to $50 million for preclinical testing and Phase 1 clinical trials. Oxford/Serum Institute of India gets up to $8.6 million for preclinical work. IAVI gets up to $3.2 million. Total: up to $61.8 million.

CEPI CEO Dr. Richard Hatchett put it plainly: "With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts."

WHO Director-General Dr. Tedros Adhanom Ghebreyesus endorsed the push, saying a Bundibugyo vaccine could "help to control this epidemic and strengthen preparedness for future outbreaks." According to WHO, these three candidates are the most promising currently in development.

None of these vaccines are going into arms during this outbreak. CNN reported May 26, 2026, that clinical-grade materials are still months away from human trials. CEPI is funding the science that might help the next outbreak — not this one.

Why There's No Vaccine — The Real Story

This is the DRC's 17th Ebola outbreak since 1976, according to CNN. Previous outbreaks in 2007 and 2012 were small — 131 cases and 38 lab-confirmed cases respectively, according to CNN. The big money and big science went toward the Zaire strain, which killed over 11,000 people in the 2014-2016 West Africa outbreak and another 3,000+ in DRC from 2018-2020.

That work produced Ervebo, a real, FDA-approved vaccine — but it targets Zaire, NOT Bundibugyo. According to WHO, its own emergency guidance document dated May 28, 2026 outlines the agency's "position on the use of the licensed Ebola virus vaccine Ervebo during Bundibugyo virus disease outbreaks" — meaning they're carefully considering whether a Zaire-targeted vaccine offers any cross-protection. Dr. Anne Ancia, WHO's representative in the DRC, confirmed to CNN that this has been under active consideration, but the data on cross-protection is limited.

Bundibugyo flew under the radar for decades. International funding and research infrastructure prioritized the Zaire strain, leaving Bundibugyo without vaccine development support before this outbreak emerged.

What Health Workers Are Actually Using Right Now

While scientists race toward future vaccines, the people in DRC are working with what exists. According to BBC, health workers are relying heavily on a device called the Cube — a transparent, self-contained treatment unit designed by the Alliance for International Medical Action (ALIMA) after the 2014-2016 outbreak.

The Cube lets medical staff treat patients through attached tunnel-like gloves without direct contact, eliminating the need for full PPE during treatment. Dr. Papys Lame, ALIMA's Ebola response coordinator, told BBC it ensures both patient care and worker protection. But the critical problem persists: there aren't enough of them.

Meanwhile, according to AP News, the UN's World Food Programme is supporting the response with cooked meals for patients and health workers — a detail that matters because malnutrition weakens immune responses and burned-out health workers quit. Basic logistics carry weight equal to cutting-edge science in an active outbreak.

The Uganda Complication

This is no longer just a DRC problem. According to WHO's official outbreak page, the Bundibugyo outbreak was confirmed in both DRC and Uganda in May 2026. WHO convened an IHR Emergency Committee on May 22, 2026, issuing temporary recommendations. A joint statement from the Government of DRC and WHO was released May 31, 2026.

Two countries. Cross-border population and trade movement. A remote, densely populated, conflict-affected region. WHO itself lists the outbreak context as: humanitarian crisis, insecurity, and high population movement. That combination is how outbreaks become epidemics.

Most mainstream coverage has kept the focus on DRC while Uganda barely gets a mention. A cross-border outbreak with no licensed vaccine and active conflict in the region is a categorically different problem than a single-country containment scenario.

What the Coverage Is Missing

Left-leaning outlets have done solid work explaining the science gap — CNN's May 26 piece by Meg Tirrell is among the better explanations of why Bundibugyo has no approved vaccine. The broader coverage, however, has not adequately examined the structural failure at the heart of this story.

The DRC has fought Ebola 17 times. The international community knew Bundibugyo existed. The funding and research infrastructure to address it existed. The decision not to invest in a Bundibugyo vaccine before this outbreak is not a mystery of nature — it's a deliberate prioritization choice by WHO, national health agencies, and global health funders who concentrated resources on Zaire and left Bundibugyo underfunded.

CEPI's $62 million now is welcome. It comes 20 years late.

The Current Situation

Three experimental vaccines are now funded and moving. They represent progress for future preparedness. Right now, in 2026, health workers in DRC and Uganda are treating patients with too few Cubes, no approved vaccine, and no specific treatment. The outbreak is already the third-largest Ebola outbreak on record and it's been public knowledge for barely two weeks.

Starting vaccine development after an epidemic begins leaves health systems to manage with existing tools. Prevention through earlier investment remains the unmet challenge.